Type 1 Gaucher disease (GD), the most prevalent lysosomal storage disease, results from the deficient activity of acid -glucosidase. Molecular analysis of 12 unrelated Portuguese patients with type 1 GD identified three novel acid -glucosidase mutations (F109V, W184R and R395P), as well as three previously reported, but uncharacterized, lesions (R359Q, G377S and N396T). The type 1 probands were either heteroallelic for the well-characterized common lesion, N370S, and the F109V, W184R, R359Q or N396T lesions or homoallelic for the G377S or N396T mutations. Expression of the W184R, R359Q, and R395P mutations revealed very low specific activities based on cross-reacting immunologic material (CRIM SAs of 0.0004, 0.016 and 0.045, respectively), consistent with their being found only in type 1 patients who had a neuroprotective N370S allele. In contrast, the F109V, G377S and N396T alleles had significant acid -glucosidase activity (CRIM specific activities of 0.15, 0.17, 0.14, respectively), in agreement with their being mild type 1 alleles. Thus, these studies identified additional acid -glucosidase mutations in the Portuguese population and demonstrated that the G377S and N396T mutations were neuroprotective, consistent with the mild clinical phenotypes of the type 1 patients who were homoallelic for the G377S and N396T lesions. European Journal of Human Genetics (2000) 8, 95-102.
Introduction
Gaucher disease (GD) is an inherited storage disorder resulting from the deficiency of acid -glucosidase (E.C.3.2. 1.45) and the lysosomal accumulation of its undegraded substrate, glucosylceramide, particularly in the cells of the reticuloendothelial system. 1, 2 The majority (about 95%) of GD cases have non-neuronopathic or type 1 disease and present with systemic features including pancytopenia, hepatosplenomegaly and skeletal involvement. 3 Patients with neurologic GD present with either an acute (type 2) or subacute (type 3) course.
The isolation and sequencing of the full-length cDNA and the entire genomic sequence, [4] [5] [6] provided the opportunity to identify common disease-causing mutations, determine their frequencies, and identify genotype/phenotype correlations. To date, over 120 mutations have been identified in the acid -glucosidase gene; 7, 8 (online compilation [http://www.uwcm.ac.uk/uwcm/mg/hgmd0.html] 9 ), including base substitutions causing missense, nonsense and splicing mutations, small and large insertions and deletions, and complex rearrangements with the pseudogene located 16 kb downstream. 6 Of these mutations, only a few have been proven to be common: the N370S lesion in the Ashkenazi Jewish and the Portuguese populations and the panethnic L444P mutation. [10] [11] [12] [13] Prediction of disease type and severity by characterizing a patient's genotype has been difficult since most of the mutations identified are rare or private. In fact, most nonconsanguineous GD patients, with the notable exception of Ashkenazi, Norbottnian, and Portuguese patients, are heteroallelic for a rare or private allele. However, genotype/ phenotype correlations have been possible for the most frequently identified mutations, N370S and L444P. 7, [14] [15] [16] [17] [18] The presence of at least one N370S allele precludes development of neurological manifestations, even if the heteroallele is completely inactive; 19, 20 and homoallelism for the L444P mutation is generally predictive of neurological disease. [21] [22] [23] [24] Nonetheless, significant phenotypic variability occurs within the subtypes, 25, 26 and in particular within type 1 GD, as illustrated by patients homoallelic for the N370S allele, whose condition, although primarily mild, can range from clinically asymptomatic to severely involved with massive hepatosplenomegaly and debilitating bone disease. Of note, type 1 GD patients homoallelic or heteroallelic for the N370S allele are unusually prevalent among Ashkenazi Jewish and non-Jewish Portuguese patients, the carrier frequencies being about 1 in 17.5 and 1 in 118 in these populations, respectively.
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The identification and expression of acid -glucosidase mutations is useful for understanding the normal function of this lysosomal hydrolase and for further delineation of genotype/phenotype correlations in GD, especially in nonJewish populations. 12, 15 Screening for four mutations (N370S, L444P, G377S and N396T) in the Portuguese population, where type 1 GD is the most prevalent lysosomal storage disease (being some 25 times more frequent than the neuronopathic forms), detected 85% of mutant or about 15% unknown alleles. 27 In this communication , three new mutations (F109V, W184R, R395P) and three previously reported  but uncharacterized lesions (R359Q,  28 G377S,  29 N396T  12 ) were detected in 12 Portuguese patients with type 1 GD. Heterologous expression and characterization studies confirmed causality of the mutations for GD, identified three mild alleles (F109V, G377S and N396T) and led to greater insight into the roles of individual residues in maintaining acid -glucosidase function.
Materials and methods

Patient descriptions
The clinical and laboratory features of the 12 Portuguese type 1 patients studied are summarized in Table 1 . The use of human materials was approved by the Institute of Medical Genetics Jacinto de Magalhães.
Reagents
Triton X-100 and NBD-glucocerebroside (NBD-Glc) were obtained from Sigma Chemical Co. (St Louis, MO, USA). DNA isolation, PCR amplification and mutation detection Genomic DNA was isolated from skin fibroblasts or peripheral blood using standard techniques. 30 Initial screening for two common (N370S, L444P) and several rare but nonfamily-specific (84GG, IVS2 + 1 , R463C, R496H, D409H, R120Q, P122S, K157Q, Y212H, F216Y, W312C, G325R, C342G, D409V, P415R, RecTL, and RecNci) mutations 21, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] as well as two mutations found in the Portuguese population, G377S 29 and N396T, 12 was performed by polymerase chain reaction (PCR) amplification and restriction digestion or allele specific oligonucleotide hybridization. 31, 45, 46 To detect the unknown acid -glucosidase mutations, the complete coding region and adjacent intron/exon boundaries were amplified directly from genomic DNA (or through nested PCR) and subjected to non-radioactive SSCP analysis. 12 The primers used for the exons in which the novel The relevant PCR products with abnormal electrophoretic mobility were further examined by direct sequencing (Sequenase Version 2.0, USB, Cleveland, Ohio, USA) of the asymmetric PCR generated products. Each mutation identified was confirmed by direct sequencing or restriction analysis of genomic DNA from the proband and affected family members. Genomic DNAs from 50 randomly selected unrelated normal individuals were screened for the F109V, W184R, and R359P mutations by restriction digestion or SSCP analysis, as described above. The designations for the mutations refer to the position of the amino acid substitution, where amino acid one is the N-terminus of the mature protein. The cDNA base numbers refer to the position of the nucleotide in the cDNA, 4, 47 where nucleotide one is the A in the first ATG. The genomic designations are based on the updated acid -glucosidase sequence 6, 48 available from GenBank [http:/ /www.ncbi.mlm.nih.gov/Entrez/nucleotide.html], accession number J03059 (8/95). The first nucleotide of exon 1 is at genomic position 1230.
Construction of expression plasmids
Point mutations for F109V, W184R, R359Q, G377S, R395P, and N396T were introduced into the acid -glucosidase cDNA by an M13mp19-based oligonucleotide-directed site-specific mutagenesis procedure (Sculptor™ In Vitro Mutagenesis System) employing the phosphorothioate selection method 49, 50 as previously described. 51, 52 The complete sequence of each mutagenized cDNA was determined to confirm that no spurious mutations were incorporated during the mutagenesis procedure. The mutant cDNAs were then cloned into the EcoRI site of the baculovirus expression vector, pVL1392. The final acid -glucosidase cDNA inserts in the expression plasmid were 1562 bp fragments beginning 12 bp upstream of the second ATG, ending at the stop codon, and containing the correct amino acid (arginine) at position 495.
Construction and purification of recombinant baculovirus
Recombinant baculovirus containing each of the different acid -glucosidase cDNAs (normal in the sense [Nl] and antisense [Rev] directions, F109V, W184R, R359Q, G377S, R395P, and N396T) were produced in cloned Spodoptera frugiperda (Sf9) cells by calcium phosphate-mediated transfection and homologous recombination between the expression plasmid and baculovirus genomic DNA (Baculogold®) as described. 53 Pure recombinant baculovirus clones containing the normal or mutant cDNA for acid -glucosidase were isolated by plaque hybridization, amplified, titered, and used at a multiplicity of infection greater than 10 to infect Sf9 cells. 53 The previously characterized common mutations, N370S and L444P, 51, 52, 54, 55 were re-expressed for comparative purposes.
Immunoblotting
Immunoelectroblotting using a polyclonal anti-human acid -glucosidase antibody was conducted as described. 56 In brief, Sf9 cells infected with pure recombinant virus were harvested 3 days post-infection. The pellets were sonicated in 0.04 M citrate/phosphate buffer, pH 5.5, containing 1 mM EDTA, 4 mM -mercaptoethanol, 0.1% Triton X-100, and 0.1% sodium taurocholate, using a probe sonicator (Heat Systems-Ultrasonics, Inc, Framingdale, NY, USA). Aliquots of the clarified (875 X g; 20 min) crude sonicates containing determined amounts of protein and enzymatic activity were run on tricine-SDS-polyacrylamide gels 57 and immunoblotted. Specific activities based on the amount of cross-reacting immunological material, CRIM specific activity (CRIM SA), were determined as described. 51, 52, 54 The relative amounts of CRIM per unit of glucosylceramide-cleaving activity for each mutant allele was determined by computer analysis of the immunoblotting membrane using the NIH Image™ program, version 1.60, and referenced to that of the normal enzyme. . F109V had a CRIM SA that was 15% of that for normal acid -glucosidase, representing a 6.7-fold reduction in catalytic efficiency or turnover rate.
Enzyme assays
Aliquots of the crude sonicates, prepared as described above, were assayed for acid -glucosidase activity using the fluorescently-labeled natural substrate NBD-GC (12-[N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)]dodecanoyl-sphingosyl-1-O--D-glucopyranoside or NBD-glucosylceramide), or the synthetic substrate, 4-methylumbelliferyl--D-glucopyranoside (4MU-Glc). The final reaction mixtures for the natural substrate contained 0.3 mM NBD-GC (reaction volume of 100 or 200 µL) in 0.04 M citrate/phosphate buffer, pH 5.5, 1 mM EDTA, 4 mM -mercaptoethanol, 0.25% Triton X-100, and 0.25% sodium taurocholate. The W184R mutant also was assayed in the presence of 2.5 mM conduritol B epoxide (CBE). The NBD-GC assays were terminated and processed as described. 58 The fluorescence of the extracted reaction products were read using a Farrand Optical System 3 spectrofluorometer (Optical Technology Devices, Elmsford, NY, USA). Background levels were determined by comparison with results obtained from Sf9 cells infected with recombinant baculovirus containing the cDNA for acid -glucosidase in the antisense direction (Rev). The contribution to turnover of the synthetic 4MU-Glc substrate in the crude lysates due to the expressed human acid -glucosidase enzymes was calculated by determining the CBE inhibitable activity. 59 Aliquots of the crude sonicates assayed were first incubated at pH 5.2 for 0.5 h at room temperature in the presence and absence of 1 mM CBE before being assayed for 2 h at 37°C. The final assay mixtures (reaction volume of 60 µL) contained 0.1/0.2 M citrate/phosphate buffer, pH 5.2, 1 mM EDTA, 4 mM -mercaptoethanol, 0.25% Triton X-100, and 0.25% sodium taurocholate. The 4MU-Glc reaction was terminated by raising the pH with the addition of 1 M glycine. The difference between the activity with and without CBE was determined for each expressed allele. One unit (U) of acid -glucosidase activity was that amount of enzyme that hydrolyzed one micromole of susbtrate per min at 37°C.
Inhibition of expressed normal and mutant acid -glucosidases by active site directed inhibitors Aliquots of crude lysates were assayed in the absence or presence of CBE and deoxynojirimycin (DNM). Concentrated aqueous stock solutions of CBE and DNM were made such that aliquots of 0-50 µL gave the desired final concentrations in the 200 µL reaction mixture. The assay conditions employing the synthetic 4MU-Glc substrate were as described above. The IC 50 (the concentration of inhibitor resulting in 50% reduction in activity) values for CBE for the normal and mutant acid -glucosidases were determined from a plot of activity remaining versus inhibitor concentration (0-600 µM) after subtracting the 4MU-Glc activity remaining at 3 mM CBE (which represents the non-CBE inhibitable endogenous Sf9-derived activity). Inhibition by DNM was assessed by determining the percentage of inhibition resulting from a single high concentration of DNM (600 µM).
Results
Identification of acid -glucosidase mutations
Complete SSCP analysis of the acid -glucosidase coding region and intron/exon boundaries from non-Jewish Portuguese patients with type 1 GD (Table 1 ) resulted in the identification of three new (F109V, W184R and R395P) and three rare, but uncharacterized, missense mutations (R359Q, 28 G377S, 29 and N396T 12 ). Table 2 summarizes the nucleotide substitutions and the corresponding changes at the protein level for each mutation. The only other allele identified in these patients was the common N370S mutation. None of these mutations were derived from the tightly linked pseudogene. 6 The W184R mutation was previously reported only as part of a complex allele 36 found in an Ashkenazi/Sephardic Jewish type 1 GD patient containing seven missense mutations (Complex C: R120W + W184R + N188K + V191G + S196P + G202R + F213I), of which all but the W184R mutation occurred in the pseudogene sequence.
As indicated in Table 2 , five of the six mutations altered a restriction site, facilitating the screening of family members to confirm the lesions. Additionally, to rule out any of the three newly identified mutations being benign polymorphisms, genomic DNA from 50 randomly selected normal Portuguese individuals was screened for the F109V, W184R and R395P mutations by restriction digestion and/or SSCP analysis. None of the 100 alleles screened had any of these new base substitutions. 
Expression and characterization of the missense mutations
The F109V, W184R, R359Q, G377S, R359P and N396T missense mutations were expressed in the baculovirus system and characterized (Table 3 ). For comparison, the previously studied N370S and L444P alleles were re-expressed. 51, 52, 54 Using the fluorescently-labeled natural substrate, NBD-GC, the expressed normal acid -glucosidase allele had approximately 9.6 ϫ 10 -2 µmol/min/mg (U/mg) of glucosylceramide-cleaving activity in the cell lysates. No activity towards NBD-GC was detected in Sf9 cells infected with the recombinant virus containing the antisense acid -glucosidase construct. All the expressed mutants had significantly reduced activities, but were relatively stable (ie there was no change in the specific activity of each mutant over a 2 h assay period). Of the six new mutants being characterized, the N396T allele had the highest residual activity (14% of normal). The F109V, G377S and R395P alleles expressed significant activity with 7, 8 and 5% of expressed normal activity, respectively. The R359Q crude lysates had slightly less (1.4% of normal), but easily detectable, residual activity. In contrast, the W184R allele had very low, but detectable activity levels (2.4 ϫ 10 -5 U/mg), which was inhibitable by CBE, an active site-directed substrate analogue specific for lysosomal acid -glucosidase. Immunoblotting studies were carried out to characterize the expressed normal and mutant acid -glucosidase and to determine if the mutations altered stability and/or catalytic efficiency. As shown in Figure 1 , lane 10, the normal human acid -glucosidase cDNA produced a multi-band pattern that strongly reacted with polyclonal anti-human acid -glucosidase antibodies. Consistent with earlier studies, 52 treatment with N-Glycanase™ demonstrated that the multiple bands with molecular weights ranging from 63 kDa to about 56 kDa represented differentially glycosylated forms of the enzyme (data not shown). Similar multi-band patterns were seen for all of the expressed mutant cDNAs. No CRIM was detected in the cells expressing the antisense acid -glucosidase construct ( Figure 1, lane 9) . To assess the level of catalytic efficiency (k cat ) for the mutant alleles, the specific activities were normalized for the relative amount of enzyme protein, ie cross-reacting immunologic material (CRIM). The CRIM SA was calculated (see Methods section) for each, relative to the expressed normal acid -glucosidase (Table 3) . Of note, the G377S, N396T and F109V mutant proteins (with CRIM SAs of 0.17, 0.14, and 0.15, respectively) had turnover rates similar to that (0.18) of the mild N370S allele. The R395P mutant protein, with its 22-fold reduced CRIM SA, had a catalytic efficiency (0.045) equivalent to that (0.057) of the L444P mutant enzyme. The R359Q allele was even more severely compromised, having only 1.6% of normal CRIM SA. Of the expressed alleles, the W184R mutant protein was essentially inactive having a 2500-fold reduction in turnover rate, and was not characterized further.
To evaluate active site function and to probe the effect of the various amino acid substitutions on the structural integrity of the active site of each expressed mutant enzyme, the affinities of two active site-directed inhibitors, CBE and DNM, were assessed. Due to its severely reduced activity, the Expression of acid -glucosidase lesions O Amaral et al y W184R mutant was excluded from these studies. For comparative purposes, the previously characterized N370S and L444P alleles were reanalyzed. 51, 52, 60 The concentration of CBE required to achieve 50% inhibition of the initial activity (IC 50 ) was determined. As shown in Figure 2 , two of the mutant proteins (F109V and G377S) interacted normally with this inhibitor, as did the L444P enzyme, and had IC 50 curves that overlapped that of the expressed normal enzyme. The findings classified these mutant proteins as typical 'group A' enzymes. 61, 62 The R359Q, R395P, N396T, and N370S mutant enzymes each had significantly reduced affinity (ie higher IC 50 values) towards CBE, categorizing them as 'group B' enzymes. These results were confirmed by determining the sensitivity of these mutant proteins to a single high concentration of DNM. Assaying the normal enzyme in the presence of 600 µM DMN resulted in an approximately 80% loss of activity towards 4MU-Glc. The 'group A' enzymes, F109V, G377S, and L444P were similarly affected, with 11, 21 and 11% activity remaining, respectively. However, the 'group B' enzymes encoded by R359Q, R395P, N396T, and N370S were inhibited less, retaining 54, 72, 63 and 76% initial activity, respectively.
Discussion
Molecular analysis of the acid -glucosidase gene from 12 unrelated Portuguese type 1 GD patients revealed three novel mutations, and the expression of these, and three other reported, but uncharacterized lesions, 12, 28, 29 provided insight into the function of these alleles and potential genotype/ phenotype correlations. The three novel mutations were missense mutations: F109V, the sterically non-conservative substitution 63, 64 of phenylalanine by valine in a weakly conserved (human vs murine 65 ) region of the acid -glucosidase protein; W184R, the non-conservative substitution of a tryptophan residue by the positively-charged arginine in the middle of 15 (amino acids 176-189) conserved (in fact, identical) residues; and R395P, the non-conservative substitution of arginine by proline, involving the loss of a positive charge and introduction of a rigid side chain at residue 395, which lies in the longest stretch (amino acids 315-406) of conserved (ie identical except for amino acid 376) residues in the human and murine sequences, suggesting an important functional domain. The three additional alleles characterized also involved residues within this highly conserved 92 amino acid region of acid -glucosidase which contains the catalytic nucleophile (E340 66 ): R359Q, the non-conservative substitution of an arginine by a glutamine (ie resulting in the loss of a positive charge); G377S, the highly favorable substitution of glycine by serine (both having small polar side chains), especially at residues with surface locations; and N396T, the conservative substitution of asparagine by the physio-chemically similar threonine. Expression studies provided the opportunity to evaluate the function of the new and previously uncharacterized mutations. The expressed recombinant mutant enzyme proteins either had severely compromised function and/or stability (W184R, R359Q and R395P), or had significant residual catalytic activity (F109V, G377S and N396T). Little, if any, functional enzyme was produced from the W184R, R359Q or R395P alleles, consistent with these mutants having severe charge or size changes in highly conserved regions of the coding sequence. Presumably, these lesions must be heteroallelic with a neuroprotective allele, such as N370S, for a type 1 disease phenotype.
Of note, the three mutations with significant residual activity had CRIM SA values (ranging from 0.14 to 0.17) similar to that (0.18) of the well-characterized common N370S allele, the 'neuroprotective' allele in type 1 GD even when heteroallelic with the most severely compromised acid -glucosidase mutation. The finding that patients homoallelic for either G377S or N396T were essentially asymptomatic or had mild disease (Table 1) suggests that these lesions also are neuroprotective. The identification of type 1 GD patients heteroallelic for either G377S or N396T and a putative or known severe allele would further substantiate the neuroprotective effect of these mutations.
In Portugal, type 1 GD is the most prevalent lysosomal storage disorder. The frequency of the N370S, L444P, G377S and N396T mutations in the Portuguese GD patients was reported as 53.7%, 13%, 7.4% and 5.6%, respectively. 12 Screening for these frequent mutations usually allows the detection of at least one allele in Portuguese patients. To date, the N396T lesion has only been reported in Portuguese type 1 GD patients. 12 In contrast, the G377S allele also has been reported in Spanish type 1 patients 67 and in a Portuguese Sephardic Jewish patient who was homoallelic for G377S, suggesting that the G377S mutation may have Sephardic ancestry. Of note, the finding of three presumably unrelated patients homoallelic for the G377S allele and four presumably unrelated patients hetero-or homoallelic for the N396T lesion suggests that these lesions have common ancestral founders in the Portuguese population.
